Arno Therapeutics Inc  

(Public, OTCMKTS:ARNI)   Watch this stock  
Find more results for arni
-0.005 (-4.55%)
Feb 17 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.10 - 0.12
52 week 0.05 - 0.92
Open 0.11
Vol / Avg. 31,100.00/43,205.00
Mkt cap 4.79M
P/E     -
Div/yield     -
EPS -0.43
Shares 49.35M
Beta -4.36
Inst. own 35%
Mar 28, 2017
Q4 2016 Arno Therapeutics Inc Earnings Release (Estimated) Add to calendar

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -893.83% -267.35%
Return on average equity - -
Employees 7 -
CDP Score - -


200 State Route 31 Ste 104
FLEMINGTON, NJ 08822-5812
United States - Map
+1-862-7037175 (Phone)
+1-908-2370071 (Fax)

Website links


Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.

Officers and directors

Arie S. Belldegrun Chairman of the Board
Age: 66
Alexander A. Zukiwski M.D. Chief Executive Officer, Chief Medical Officer, Vice President, Director
Age: 57
Stefan Proniuk Ph.D. Chief Development Officer
Age: 44
David M. Tanen Secretary, Director
Age: 43
Jay Moorin Director
Age: 64
William F. Hamilton Ph.D. Independent Director
Age: 75
Tomer Kariv J.D. Independent Director
Age: 55
Yacov Reizman Independent Director
Age: 63
Steven B. Ruchefsky Independent Director
Age: 53